Vor Biopharma’s (VOR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Vor Biopharma (NYSE:VOR) in a report released on Tuesday morning,Benzinga reports. They currently have a $17.50 price objective on the stock.

A number of other equities analysts also recently issued reports on VOR. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a report on Friday, September 6th. Robert W. Baird decreased their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Barclays dropped their price objective on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Vor Biopharma in a research note on Monday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $11.36.

Vor Biopharma Stock Performance

Shares of VOR opened at $0.98 on Tuesday. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $3.14. The firm’s 50-day moving average price is $0.80 and its 200-day moving average price is $0.93. The firm has a market capitalization of $67.17 million, a price-to-earnings ratio of -0.59 and a beta of -0.37.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). On average, research analysts forecast that Vor Biopharma will post -1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC raised its stake in shares of Vor Biopharma by 51.4% in the second quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after purchasing an additional 27,597 shares during the last quarter. Vanguard Group Inc. raised its position in Vor Biopharma by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after buying an additional 69,436 shares during the last quarter. Hsbc Holdings PLC lifted its stake in Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after acquiring an additional 31,333 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Vor Biopharma during the 2nd quarter valued at about $53,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vor Biopharma in the second quarter worth approximately $63,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.